Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas

More active high-dose regimens are needed for refractory/poor-risk relapsed lymphomas. We previously developed a regimen of infusional gemcitabine/busulfan/melphalan, exploiting the synergistic interaction. Its encouraging activity in refractory lymphomas led us to further enhance its use as a platf...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Biol Blood Marrow Transplant
Prif Awduron: Nieto, Yago, Valdez, Benigno C., Thall, Peter F., Ahmed, Sairah, Jones, Roy B., Hosing, Chitra, Popat, Uday, Shpall, Elizabeth J., Qazilbash, Muzaffar, Gulbis, Alison, Anderlini, Paolo, Alousi, Amin, Shah, Nina, Bashir, Qaiser, Liu, Yan, Oki, Yasuhiro, Hagemeister, Frederick, Fanale, Michelle, Dabaja, Bouthaina, Pinnix, Chelsea, Champlin, Richard, Andersson, Borje S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4781754/
https://ncbi.nlm.nih.gov/pubmed/26071868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.06.003
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg